Evidence map›Paper›PMID 32938212›Full record

ArticleFuture oncology (London, England)2020

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, Laurent Mortier, Andrew S Brohl, Nicola Fazio, Jean-Jacquez Grob, Sara Pusceddu, Glenn J Hanna, Jessica C Hassel and 9 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02155647 (A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02155647 phase2completednot on this map

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

TypeinterventionalSponsorEMD Serono Research & Development Institute, Inc.Ran2014 to 2023Enrolled204ConditionsCarcinoma, Merkel CellArmsAvelumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 4 countries.

Murtuza BharmalEMD Serono Research & Development Institute, Inc., Rockland, MA 02370, USA; a business of Merck KGaA, Darmstadt, Germany.ORCID https://orcid.org/0000-0001-7689-5769
Sandra NolteICON plc, Munich, Germany/Lyon, France.ORCID https://orcid.org/0000-0001-6185-9423
Céleste LebbéUniversité de Paris, INSERM U976 & Dermatology & CIC, AP-HP, Saint Louis Hospital, Paris, France.
Laurent MortierDepartment of Dermatology, CARADERM and University of Lille, Inserm U1189, CHU Lille, Lille Cedex, France.
Andrew S BrohlMoffitt Cancer Center, Tampa, FL 33612, USA.
Nicola FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Jean-Jacquez GrobAix-Marseille University, AP-HM Hospital, Marseille, France.
Sara PuscedduDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Glenn J HannaDana-Farber Cancer Institute, Boston, MA 02215, USA.
Jessica C HasselDepartment of Dermatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-7575-6230
Felix KieckerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Berlin Institute of Health, Berlin, Germany.
Barbara Ellers-LenzMerck KGaA, Darmstadt, Germany.
Marcis BajarsEMD Serono Research & Development Institute, Inc., Billerica, MA 01821, USA; a business of Merck KGaA, Darmstadt, Germany.
Gülseren GüzelMerck KGaA, Darmstadt, Germany.
Paul NghiemDivision of Dermatology, University of Washington Medical Center at South Lake Union, Seattle, WA 98109, USA.
Matthias HungerICON plc, Munich, Germany/Lyon, France.
Michael SchlichtingMerck KGaA, Darmstadt, Germany.
Mickaël Henry-SzatkowskiICON plc, Munich, Germany/Lyon, France.
Sandra P D'AngeloDepartment of Medicine, Weill Cornell Medical College & Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Merck (Germany) · DEHumboldt-Universität zu Berlin · DEInserm · FRAix-Marseille Université · FRDana-Farber Cancer Institute · USFondazione IRCCS Istituto Nazionale dei Tumori · ITHeidelberg University · DEIstituti di Ricovero e Cura a Carattere Scientifico · ITMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USUniversity of Washington Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Understand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI Cecilia C Yeung · 2019 to 2026
$22.7M
NCI NIH HHS P01 CA225517NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Quality of LifeAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCarcinoma, Merkel CellClinical Trials, Phase II as TopicDisease ProgressionFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedMolecular Targeted TherapyPatient Reported Outcome MeasuresPrognosisTreatment OutcomeAntibodies, Monoclonal, HumanizedavelumabImmune Checkpoint InhibitorsFACT-M questionnairehealth-related quality of lifeMerkel cell carcinomapatient reported outcomeself report

Identifiers

PMID32938212
PMCPMC9437770
OpenAlexW3087335736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.